Sign in

    Cooper Companies Inc (COO)

    Q3 2024 Earnings Summary

    Reported on Jan 10, 2025 (After Market Close)
    Pre-Earnings Price$94.54Last close (Aug 28, 2024)
    Post-Earnings Price$104.10Open (Aug 29, 2024)
    Price Change
    $9.56(+10.11%)

    What went well

    • Strong Operational Momentum with Expected Low Double-Digit Operating Income Growth: The management emphasized their commitment to delivering low double-digit constant currency operating income growth for fiscal 2025, indicating strong operational momentum going into next year. They expect stronger free cash flow, allowing for debt repayment, and potential upside from positive foreign exchange impacts.
    • Improving Gross Margins Through Pricing and Efficiency Gains: Despite potential headwinds from expanding daily contact lens products, the company is successfully offsetting these with price increases and efficiency gains, particularly in intercompany shipping and infrastructure investments. This efficiency is contributing to improved gross margins, with expectations to continue increasing margins over the longer term.
    • Positive Product Mix Shift Enhancing Long-Term Margins: Growth in higher-margin products such as toric and multifocal lenses is driven by innovative offerings like Energys. This product mix shift is contributing to higher prices and improved operating margins over time, supporting long-term accretive benefits to the company's profitability.

    What went wrong

    • Cooper Companies is facing challenges in the Chinese market for its myopia management products, with the CEO admitting that China is "a market where we struggle," limiting growth potential in a significant market.
    • The company is dealing with potential litigation from a culture media recall in its fertility business, which could pose financial risks despite having insurance coverage.
    • An expected increase in the effective tax rate year-over-year may impact earnings per share growth in fiscal 2025.

    Q&A Summary

    1. Fiscal 2025 Outlook
      Q: Will OI growth lead to higher EPS in '25?
      A: Management affirmed their goal of low double-digit constant currency operating income growth for fiscal 2025 ,. Stronger free cash flow will allow for debt reduction, lowering interest expenses ,. FX is currently a positive, and while the effective tax rate will be higher next year (above 15.5% this year), overall this should result in decent EPS growth ,.

    2. Capacity Expansion
      Q: Are capacity constraints being resolved to meet demand?
      A: Demand still exceeds supply, especially for the MyDay product line , ,. The company is bringing capacity online, improving their ability to meet demand and enabling incremental launch activities ,. This progress makes them optimistic about future growth as they expand capabilities ,.

    3. Market Conditions
      Q: Is the contact lens market softening?
      A: The market remains healthy globally and in the U.S.. Despite occasional noise like consumer rebates, the market shows continued growth, especially in mid- and higher-end products like torics and multifocals.

    4. Pricing Outlook
      Q: How are you approaching pricing in fiscal '25?
      A: The company plans to raise prices again in fiscal Q1 to offset inflation ,. With inflation around 3%, they expect industry price increases in the 2–3% range to support market growth ,.

    5. Margin Maintenance
      Q: How are you maintaining strong margins?
      A: Price and efficiency gains are offsetting FX headwinds. Improvements in intercompany shipping and infrastructure have enhanced gross margins. While dailies are a headwind, continuous improvement activities will help increase gross margins over time.

    6. Myopia Management Growth
      Q: What's driving growth in myopia management?
      A: Myopia management generated about $37 million this quarter, with MiSight now larger than ortho-K ,. Adoption is in early stages, but global interest is growing ,. Anticipated FDA approval of spectacles could significantly expand the market ,.

    7. PARAGARD Outlook
      Q: What's the outlook for PARAGARD amid competition?
      A: PARAGARD is expected to be slightly up this year , despite a declining IUD market. The new single-hand inserter improves practitioner efficiency, putting PARAGARD on par with competitors ,. Management is confident due to its unique 10-year indication and strong market position.

    8. APAC Growth
      Q: Why was APAC growth softer?
      A: APAC sales were softer due to supply constraints; more product is needed to meet demand. The company is working to bring more capacity online, particularly for MyDay, to support regional growth.

    9. Operating Expense Leverage
      Q: What drove SG&A leverage this quarter?
      A: Both businesses executed well, achieving meaningful SG&A leverage. Investments over recent years are yielding efficiencies and positive returns. This trend is expected to continue into next quarter and beyond.

    10. Competitive Position
      Q: Are you concerned about competitors reclaiming share?
      A: Management is not worried about competitors reversing decisions like reinstating toric SKUs. They believe their market-leading toric products retain patients. Their consistent performance is due to a broad portfolio and strong products across segments.

    11. Distributor Issue Impact
      Q: Did last quarter's distributor issue affect sales?
      A: The CooperSurgical IT upgrade issue disrupted sales slightly into this quarter but has been resolved. A residual upside is expected in Q4, with CooperSurgical growth guided at 6–8%.

    Related Publications